LEADERSHIP 核心团队

World-class scientists & drug developers 世界级科学家与药物开发者

Our founding team combines decades of innovative drug discovery with top-tier AI, structural biology, and clinical research credentials — and a track record of delivering approved therapies. 我们的创始团队融合了数十年的创新药研发经验，以及世界一流的 AI、结构生物学 与临床研究背景 —— 更有主导多款获批新药上市的实战业绩。

Founding Team 创始团队

Scientific leadership 科研领导力

杨
Dr. Jie Yang 杨杰 博士
Founder & Chief Technology Officer 创始人兼首席技术官 (CTO)
Dr. Yang brings 20+ years of innovative drug discovery and CMC management experience spanning academia and industry in the US and China. He led and contributed to the development of two FDA/NMPA approved drugs: Tibsovo® (ivosidenib) — the first IDH1 inhibitor approved for AML — and Ru Jianing® (瑞佳宁). During his 10+ years in the United States, he participated in NIH-funded programs totaling over $10M. Dr. Yang is the principal architect of GenTide's DTBL platform and oversees technology strategy, pipeline execution, and CMC development. 杨杰博士拥有 20+ 年横跨中美学术界与产业界的创新药研发与 CMC 管理经验。 主导及参与 2 款 FDA/NMPA 获批新药开发：Tibsovo®（ivosidenib）—— 全球首个获批 IDH1 抑制剂，用于急性髓系白血病；以及瑞佳宁®。 在美国工作期间，参与 NIH 资助项目累计规模超过 1000 万美元。 杨杰博士是 GenTide DTBL 平台的核心架构师，统筹技术战略、管线执行与 CMC 开发。
Postdoc, U. Minnesota 明尼苏达大学博士后 PhD, Duquesne University 杜肯大学博士 30+ SCI 12+ Patents NIH $10M+
唐
Prof. Tang Yun 唐贇 教授
Chief Scientific Officer 首席科学官 (CSO)
Prof. Tang is a Full Professor at ECUST School of Pharmacy and Director of the Shanghai Key Laboratory of New Drug Design. He received his PhD from the Shanghai Institute of Materia Medica (CAS) under Academicians Chen Kaixian and Ji Ruyun, completed his postdoc at Karolinska Institute (Sweden), and was a visiting scholar at NIH/NCI (USA). His research group developed key GenTide platform algorithms: NBI/SDTNBI/wSDTNBI (770+ citations), admetSAR 3.0 (2M+ global uses), CLaSP, SGEDiff, and ComplexDnet. Recognized as Elsevier "Highly Cited Chinese Researcher" and Stanford "Top 2% Global Scientists." He serves as an editorial board member of ACS Journal of Chemical Information and Modeling (JCIM). 唐贇教授现任华东理工大学药学院教授、上海市新药设计重点实验室主任。 于中国科学院上海药物研究所师从陈凯先院士、嵇汝运院士获博士学位； 后赴瑞典卡洛林斯卡医学院从事博士后研究，并担任美国 NIH/NCI 访问学者。 其团队开发了 GenTide 平台的核心算法：NBI/SDTNBI/wSDTNBI（被引 770+ 次）、 admetSAR 3.0（全球使用量 200 万+）、CLaSP、 SGEDiff、ComplexDnet。 Elsevier "中国高被引学者"，斯坦福大学"全球前 2% 顶尖科学家"。 现任 ACS JCIM 期刊编委。
300+ SCI 14,000+ Citations 10 Patents ACS JCIM Editor ACS JCIM 编委 Stanford Top 2% 斯坦福前 2%
赵
Dr. Zhao Chao 赵超 教授
Chief Medical Officer 首席医学官 (CMO)
Dr. Zhao is a PI and Researcher at the National Clinical Research Center for Aging and Medicine (Huashan Hospital, Fudan University) and an Associate Professor at Fudan University School of Basic Medical Sciences. He is the discoverer of GenTide's most original scientific asset — the PAGln/PAA pro-aging mechanism published in Nature Aging (2024), which identifies gut microbiota metabolites as upstream drivers of β2-AR-mediated cellular senescence. His lab has built the proprietary p16-Luciferase reporter mouse HTS system and validated ARPE19/HEK293 cell assay platforms that form the foundation of the β2-AR pipeline. His research spans gut microbiota, aging biology, emotional regulation, and tumor microenvironment, published in Nature, Nature Aging, and Cell Metabolism. He has attracted over ¥10M in competitive research grants. 赵超博士现任国家老年疾病临床医学研究中心（复旦大学附属华山医院）研究员与 PI， 复旦大学基础医学院副教授。他是 GenTide 最具原创性科学资产的发现者—— PAGln/PAA 促衰老机制发表于 Nature Aging（2024）， 揭示肠道菌群代谢产物是 β2-AR 介导细胞衰老的上游驱动因素。 其团队建立了独家 p16-Luciferase 报告基因小鼠 HTS 体系 与经验证的 ARPE19/HEK293 细胞测试平台，构成 β2-AR 管线的验证基础设施。 研究成果发表于 Nature、Nature Aging、Cell Metabolism，获批竞争性科研经费逾 1000 万元。
Nature Nature Aging Cell Metabolism ¥10M+ Grants 1000万+ 科研经费 Fudan University 复旦大学
Track Record 成就与荣誉

Recognition from industry, academia, and investors 产业、学界、投资方的多重认可

🏆

SJTU 2025 "Future Star" Enterprise 上海交大 2025 "未来之星"企业

Recognized for innovation and commercialization potential. 因创新性与商业化潜力获选。

🥇

SJTU Top Vertical Model — 1st Prize 上海交大垂类大模型 一等奖

Awarded for our AI drug discovery vertical model. 因 AI 药物发现垂类大模型获奖。

🌟

14th China Innovation & Entrepreneurship Competition 第十四届中国创新创业大赛

Outstanding Enterprise award. 优秀企业奖。

🎖️

2025 Shanghai International Innovation Competition 2025 上海国际创新大赛

Outstanding Enterprise award. 优秀企业奖。